Back to Browse Journals » Clinical Ophthalmology » Volume 1 » Issue 4

Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

Authors Cleber A Trujillo, Arthur A Nery, Janaí­na M Alves, Antonio H Martins, Henning Ulrich

Published Date January 2007 Volume 2007:1(4) Pages 393—402

DOI

Published 10 January 2007

Cleber A Trujillo1, Arthur A Nery1, Janaína M Alves2, Antonio H Martins1, Henning Ulrich1

1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil; 2Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil

Abstract: Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects.

Keyword: anti-VEGF aptamer, pegaptanib, age-related macular degeneration

Download Article [PDF] 

Readers of this article also read:

Differential stress reaction of human colon cells to oleic-acid-stabilized and unstabilized ultrasmall iron oxide nanoparticles

Schütz CA, Staedler D, Crosbie-Staunton K, Movia D, Chapuis Bernasconi C, Kenzaoui BH, Prina-Mello A, Juillerat-Jeanneret L

International Journal of Nanomedicine 2014, 9:3481-3498

Published Date: 23 July 2014

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Delivery of a transforming growth factor β-1 plasmid to mesenchymal stem cells via cationized Pleurotus eryngii polysaccharide nanoparticles

Deng WW, Cao X, Wang M, Qu R, Su WY, Yang Y, Wei YW, Xu XM, Yu JN

International Journal of Nanomedicine 2012, 7:1297-1311

Published Date: 14 March 2012

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011

Emerging role of brain metastases in the prognosis of breast cancer patients

Hambrecht A, Jandial R, Neman J

Breast Cancer: Targets and Therapy 2011, 3:79-91

Published Date: 10 August 2011

Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans

Farzaneh A Sorond, Lewis A Lipsitz, Norman K Hollenberg, Naomi DL Fisher

Neuropsychiatric Disease and Treatment 2008, 4:433-440

Published Date: 16 April 2008

Retinopathy among type 2 diabetic patients seen at a tertiary hospital in Nigeria: a preliminary report

Adeyinka Ashaye, Ayodeji Arije, Modupe Kuti, Bolutife Olusanya, Ezekiel Ayeni, et al

Clinical Ophthalmology 2008, 2:103-108

Published Date: 17 March 2008

Cyclosporin-A associated malignancy

Jonathan M Durnian, Rosalind MK Stewart, Richard Tatham, Mark Batterbury, Stephen B Kaye

Clinical Ophthalmology 2007, 1:421-430

Published Date: 10 January 2007